BUSINESS
Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
Drug makers are racing to develop what is believed to be next-generation renal anemia therapies, called hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, with at least five compounds in development in Japan that could offer an alternative to erythropoietin-stimulating agents (ESAs)…
To read the full story
Related Article
BUSINESS
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
May 22, 2026
- Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
May 22, 2026
- SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





